Skip to main content
SpringerLink
Log in

Effect of enalapril on plasma homocysteine levels in patients with essential hypertension

  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Objective

To investigate the effect of enalapril on plasma homocysteine (Hcy) levels and the association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism with the changes of Hcy levels in response to enalapril among patients with essential hypertension.

Methods

A total of 130 patients with mild-to-moderate essential hypertension were enrolled and enalapril was orally administered at a dose of 10 mg/d for eight weeks. Plasma Hcy levels were measured by denaturing high-performance liquid chromatography (DHPLC) at baseline and after eight weeks of treatment. Genotyping of MTHFR C677T polymorphism was performed by TaqMan probe technique.

Results

Compared with baseline, plasma Hcy levels did not change significantly after eight weeks (P=0.81). Stratified by baseline Hcy levels, a significant increase in plasma Hcy levels (P=0.02) among those with Hcy <10 μmol/L was observed, in contrast to no significant changes in plasma Hcy levels (P=0.54) among those with Hcy ≥10 μmol/L. No significant association was observed between MTHFR C677T polymorphism and changes in Hcy levels in response to enalapril.

Conclusions

Enalapril may cause an increase in plasma Hcy levels among the hypertensives with low baseline Hcy levels. There was no significant association between MTHFR C677T genotypes and changes in Hcy levels in response to enalapril among subjects with essential hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andersson, A., Brattström, L., Israelsson, B., Isaksson, A., Hamfelt, A., Hultberg, B., 1992. Plasma homoeysteine before and after methionine loading with regard to age, gender and menopausal status. European Journal of Clinical Investigation, 22(2):79–87. [doi:10.1111/j.1365-2362.1992.tb01940.x]

    Article  CAS  PubMed  Google Scholar 

  • Atar, I., Korkmaz, M.E., Demircan, S., Atar, I.A., Bozbaş, H., Aydinalp, A., Ozin, B., Yildirir, A., Müderrisoğlu, H., 2005. Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis, 181(2):399–402. [doi:10.1016/j.atherosclerosis.2005.01.035]

    Article  CAS  PubMed  Google Scholar 

  • Bots, M.L., Launer, L.J., Lindemans, J., Hoes, A.W., Hofman, A., Witteman, J.C., Koudstaal, P.J., Grobbee, D.E., 1999. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Archives of Internal Medicine, 159(1):38–44. [doi:10.1001/archinte.159.1.38]

    Article  CAS  PubMed  Google Scholar 

  • Boushey, C.J., Beresford, S.A., Omenn, G.S., Motulsky, A.G., 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. The Journal of the American Medical Association, 274(13):1049–1057. [doi:10.1001/jama.274.13.1049]

    Article  CAS  Google Scholar 

  • Brattstrom, L., Lindgren, A., Israelsson, B., Andersson, A., Hultberg, B., 1994. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. Journal of Internal Medicine, 236(6):633–641. [doi:10.1111/j.1365-2796.1994.tb00856.x]

    Article  CAS  PubMed  Google Scholar 

  • Desouza, C., Keebler, M., McNamara, D.B., Fonseca, V., 2002. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs, 62(4):605–616. [doi:10.2165/00003495-200262040-00005]

    Article  CAS  PubMed  Google Scholar 

  • Dierkes, J., Westphal, S., 2005. Effect of drugs on homocysteine concentrations. Seminars in Vascular Medicine, 5(2):124–139. [doi:10.1055/s-2005-872398]

    Article  PubMed  Google Scholar 

  • Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., Boers, G.J., den Heijer, M., Kluijtmans, L.A., van den Heuvel, L.P., et al., 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics, 10(1):111–113. [doi:10.1038/ng0595-111]

    Article  CAS  PubMed  Google Scholar 

  • Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattström, L.E., Ueland, P.M., Palma-Reis, R.J., Boers, G.H., Sheahan, R.G., Israelsson, B., et al., 1997. Plasma homocysteine as a risk factor for vascular disease. The Eumpean Concerted Action Project. The Journal of the American Medical Association, 277(22):1775–1781. [doi:10.1001/jama.277.22.1775]

    Article  CAS  Google Scholar 

  • Gu, D.F., He, J., Wu, X.G., Duan, X.F., Yao, C.H., Wang, J.L., Reynolds, K., Chen, C.S., Klag, M.J., Whelton, P.K., 2006. Main causes and its modifiable risks of death among men and women in China. Chinese Journal of Prevention and Control of Chronic Non-communicable Diseases, 14(3):149–154 (in Chinese).

    Google Scholar 

  • Guilliams, T.G., 2004. Homocysteine-a risk factor for vascular diseases: guidelines for the clinical practice. The Journal of the American Nutraceutical Association, 7(1):11–24.

    Google Scholar 

  • Homomcysteine Studies Collaboration, 2002. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. The Journal of the American Medical Association, 288(16):2015–2022.

    Article  Google Scholar 

  • Hu, D.Y., Xu, X.P., 2008. Prevention of stroke relies on valid control “H” type hypertension. Chinese Journal of Internal Medicine, 47(12):976–977 (in Chinese).

    Google Scholar 

  • Huang, H.W., Guo, M.H., Huang, J.X., Lin, R.J., Zhang, Y., Chen, Y.L., 2006. The analysis of plasma homocysteine among 1020 residents in community. Chinese Journal of Epidemiology, 27(8):721–724 (in Chinese).

    CAS  PubMed  Google Scholar 

  • Jacques, P.F., Bostom, A.G., Williams, R.R., Ellison, R.C., Eckfeldt, J.H., Rosenberg, I.H., Selhub, J., Rozen, R., 1996. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 93(1):7–9.

    CAS  PubMed  Google Scholar 

  • Jacques, P.F., Bostom, A.G., Wilson, P.W., Rich, S., Rosenberg, I.H., Selhub, J., 2001. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. The American Journal of Clinical Nutrition, 73(3):613–621.

    CAS  PubMed  Google Scholar 

  • Jiang, S., Hsu, Y.H., Xu, X., Xing, H., Chen, C., Niu, T., Zhang, Y., Peng, S., Xu, X., 2004. The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thrombosis Research, 113(6):361–369. [doi:10.1016/j.thromres.2004.04.005]

    Article  CAS  PubMed  Google Scholar 

  • Kjeldsen, S.E., Julius, S., Hedner, T., Hansson, L., 2001. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Pressure, 10(4):190–192. [doi:10.1080/08037050152669684]

    Article  CAS  PubMed  Google Scholar 

  • Li, J.P., Huo, Y., Liu, P., Qin, X.H., Guan, D.M., Ge, J.B., Hu, J., Wang, Y.N., Zhang, F.M., Mao, G.Y., et al., 2007. Efficacy and safety of enalapril-folate acid tablets in lowering blood pressure and plasma homocysteine. Journal of Peking University: Health Sciences, 39(6):614–618 (in Chinese).

    Google Scholar 

  • Madero, M., Sarnak, M.J., Stevens, L.A., 2006. Serum cystatin C as a marker of glomerular filtration rate. Current Opinion in Nephrology and Hypertension, 15(6):610–616. [doi:10.1097/01.mnh.0000247505.71915.05]

    Article  CAS  PubMed  Google Scholar 

  • McNulty, H., Pentieva, K., Hoey, L., Ward, M., 2008. Homocysteine, B-vitamins and CVD. The Proceedings of the Nutrition Society, 67(2):232–237. [doi:10.1017/S0029665108007076]

    Article  CAS  PubMed  Google Scholar 

  • Nygård, O., Vollset, S.E., Refsum, H., Stensvold, I., Tverdal, A., Nordrehaug, J.E., Ueland, M., Kvåle, G., 1995. Total plasmahomocystein and cardiovaseular risk Profile. The Hordaland Homoeystein study. The Journal of the American Medical Association, 274(19):1526–1533. [doi:10.1001/jama.274.19.1526]

    Article  Google Scholar 

  • Poduri, A., Kaur, J., Thakur, J.S., Kumari, S., Jain, S., Khullar, M., 2008. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension. Journal of Human Hypertension, 22(4):289–294. [doi:10.1038/sj.jhh.1002325]

    Article  CAS  PubMed  Google Scholar 

  • Rong, R., Zhang, A.M., Fan, C.H., Zhang, Z., 2009. The analysis of the relationship between serum homocysteine (HCY) and chemistries in patients of coronary heart disease. Chinese Journal of Laboratory, 13(1):77–80 (in Chinese).

    Google Scholar 

  • Sacco, R.L., Adams, R., Albers, G., Alberts, M.J., Benavente, O., Furie, K., Goldstein, L.B., Gorelick, P., Halperin, J., Harbaugh, R., et al., 2006. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. Stroke, 37(2):577–617. [doi:10.1161/01.STR.0000199147.30016.74]

    Article  PubMed  Google Scholar 

  • Saposnik, G., Ray, J.G., Sheridan, P., McQueen, M., Lonn, E., Heart Outcomes Prevention Evaluation 2 Investigators, 2009. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke, 40(4):1365–1372. [doi:10.1161/STROKEAHA.108.529503]

    Article  CAS  PubMed  Google Scholar 

  • Šebeková, K., Gazdíková, K., Syrová, D., Blazícek, P., Schinzel, R., Heidland, A., Spustová, V., Dzúrik, R., 2003. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. Journal of Human Hypertension, 17(4):265–270. [doi:10.1038/sj.jhh.1001541]

    Article  PubMed  Google Scholar 

  • Spence, J.D., Howard, V.J., Chambless, L.E., Malinow, M.R., Pettigrew, L.C., Stampfer, M., Toole, J.F., 2001. Vitamin intervention for stroke prevention (VISP) trial: rationale and design. Neuroepidemiology, 20(1):16–25. [doi:10.1159/000054753]

    Article  CAS  PubMed  Google Scholar 

  • Sun, Y., Chien, K.L., Hsu, H.C., Su, T.C., Chen, M.F., Lee, Y.T., 2009. Use of serum homocysteine to predict stroke, coronary heart disease and death in Ethnic Chinese: a 12-year prospective cohort study. Circulation Journal, 73(8):1423–1430. [doi:10.1253/circj.CJ-08-1077]

    Article  PubMed  Google Scholar 

  • Sunder-Plassmann, G., Födinger, M., 2003. Genetic determinants of the homocysteine level. Kidney International, 63(s84):141–144. [doi:10.1046/j.1523-1755.63.s84.52.x]

    Article  Google Scholar 

  • Trabetti, E., 2008. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. Journal of Applied Genetics, 49(3):267–282.

    PubMed  Google Scholar 

  • Ueland, P.M., Refsum, H., Stabler, S.P., Malinow, M.R., Andersson, A., Allen, R.H., 1993. Total homocysteine in plasma or serum: methods and clinical applications. Clinical Chemistry, 39(9):1764–1779.

    CAS  PubMed  Google Scholar 

  • Ueland, P.M., Hustad, S., Schneede, J., Refsum, H., Vollset, S.E., 2001. Biological and clinical implications of the MTHFR C677T polymorphism. Trends in Pharmacological Sciences, 22(4):195–201. [doi:10.1016/S0165-6147(00)01675-8]

    Article  CAS  PubMed  Google Scholar 

  • Verhoef, P., Kok, F.J., Kluijtmans, L.A., Blom, H.J., Refsum, H., Ueland, P.M., Kruyssen, D.A., 1997. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis, 132(1):105–113. [doi:10.1016/S0021-9150(97)00084-1]

    Article  CAS  PubMed  Google Scholar 

  • Wald, D.S., Law, M., Morris, J.K., 2002. Homocysteine and CVD: evidence on causality from a meta-analysis. BMJ (Clinical Research Ed.), 325(7374):1202. [doi:10.1136/bmj.325.7374.1202]

    Article  Google Scholar 

  • Wang, X., Qin, X., Demirtas, H., Li, J., Mao, G., Huo, Y., Sun, N., Liu, L., Xu, X., 2007. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet, 369(9576):1876–1882. [doi:10.1016/S0140-6736(07)60854-X]

    Article  CAS  PubMed  Google Scholar 

  • Wang, Y.J., Liu, L.S., Rao, K.Q., Xu, X.P., 2008. Thoughts for prevention of stroke in China: control both hypertension and hyperhomocysteinemia. National Medical Journal of China, 88(47):3316–3318 (in Chinese).

    PubMed  Google Scholar 

  • Westphal, S., Rading, A., Luley, C., Dierkes, J., 2003. Antihypertensive treatment and homocysteine concentrations. Metabolism, 52(3):261–263. [doi:10.1053/meta.2003.50060]

    Article  CAS  PubMed  Google Scholar 

  • Xu, Y.L., Zhang, S.C., Li, J.P., Wang, M.D., Xing, H.X., Zang, T.H., Huo, Y., Xu, X.P., 2006. The modification of MTHFR gene polymorphism effect of the correlation between serum folic acid and plasma homocysteine. Acta Universitatis Medicinalis Anhui, 41(6):639–642 (in Chinese).

    CAS  Google Scholar 

  • Yang, Q., Botto, L.D., Erickson, J.D., Berry, R.J., Sambell, C., Johansen, H., Friedman, J.M., 2006. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation, 113(10):1335–1343. [doi:10.1161/CIRCULATIONAHA.105.570846]

    Article  PubMed  Google Scholar 

  • Zhan, Y.Q., Jin, Y., Li, Y.Z., 2001. A general introduction of clinical application of angiotension converting enzyme inhibitors. China Licensed Pharmacist, 7(1):3–6 (in Chinese).

    Google Scholar 

  • Zhao, D., Liu, J., Wang, W., Zeng, Z., Cheng, J., Liu, J., Sun, J., Wu, Z., 2008. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke, 39(6):1668–1674. [doi:10.1161/STROKEAHA.107.502807]

    Article  PubMed  Google Scholar 

  • Zhu, L.H., Xu, G.B., Yang, H.Y., 2001. Homocysteine and atherosclerosis. Chinese Journal of Laboratory Medicine, 24(2):121–123 (in Chinese).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Peking University First Hospital, Beijing, 100034, China

    Fang-fang Fan, Yong Huo & Jian-ping Li

  2. Institute of Biomedicine, Anhui Medical University, Hefei, 230032, China

    Xu Wang, Xin Xu, Bin-yan Wang & Xi-ping Xu

Authors
  1. Fang-fang Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin-yan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xi-ping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian-ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-ping Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fan, Ff., Huo, Y., Wang, X. et al. Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J. Zhejiang Univ. Sci. B 11, 583–591 (2010). https://doi.org/10.1631/jzus.B1001003

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1001003

Key words

CLC number

Search

Navigation